Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 16/20 | 0.51 |
| ▸ | RAB7A | P51149 | 2/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 8/20 | 0.45 |
| ▸ | PTPRC | P08575 | 2/20 | 0.45 |
| ▸ | PTPRB | P23467 | 2/20 | 0.45 |
| ▸ | PTPRE | P23469 | 2/20 | 0.45 |
| ▸ | PTPRA | P18433 | 2/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838812 | 0.93 | PTPN1 (0.46) | PTPN1RAB7APTPN2PTPRCPTPRB | |
| SCHEMBL6314433 | 0.91 | PTPN1 (0.46) | PTPN1RAB7APTPN2PTPRCPTPRB | |
| SCHEMBL5837429 | 0.90 | PTPN1 (0.45) | PTPN1RAB7APTPN2PTPRCPTPRB | |
| SCHEMBL6323723 | 0.90 | PTPN1 (0.46) | PTPN1RAB7APTPN2PTPRCPTPRB | |
| SCHEMBL6314944 | 0.90 | PTPN1 (0.45) | PTPN1RAB7APTPN2PTPRCPTPRB | |
| SCHEMBL5837692 | 0.90 | PTPN1 (0.42) | PTPN1RAB7APTPN2PTPRCPTPRB | |
| SCHEMBL5837624 | 0.90 | PTPN1 (0.44) | PTPN1RAB7APTPN2PTPRCPTPRB | |
| SCHEMBL5837077 | 0.90 | PTPN1 (0.48) | PTPN1RAB7APTPN2PTPRCPTPRB | |
| SCHEMBL5838650 | 0.90 | PTPN1 (0.44) | PTPN1RAB7APTPN2PTPRCPTPRB | |
| SCHEMBL6322684 | 0.90 | PTPN1 (0.46) | PTPN1RAB7APTPN2PTPRCPTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1214325-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2005-11-09 | — | — | EP | claimed |
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | MOLLER NIELS PETER HUNDAHL (DK) | 2003-04-10 | — | — | US | claimed |
| EP-1080095-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2001-03-07 | — | — | EP | claimed |
| WO-1999046267-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | claimed |
| EP-1214325-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2005-11-09 | — | — | EP | disclosed |
| US-6951878-B2 | Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2005-10-04 | — | — | US | disclosed |
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | MOLLER NIELS PETER HUNDAHL (DK) | 2003-04-10 | — | — | US | disclosed |
| US-6410586-B1 | ANTICOAGULANTS; INSULIN RESISTANCE; ANTIALLERGENS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| US-6262044-B1 | CONTAINING AN AMIDE-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE RING | NOVO NORDISK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| EP-1080095-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| EP-1080068-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | Novo Nordisk A/S (DK) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999046267-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999046237-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES | NOVO NORDISK A/S (DK) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPRA | PTPN1 7/4885RAB7A 3644/4885PTPN2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.